XLONDXRX
Market cap143mUSD
Jan 03, Last price
136.50GBP
1D
0.37%
1Q
2.63%
IPO
40.00%
Name
Diaceutics PLC
Chart & Performance
Profile
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX patient journey that enables pharma customers to complete a longitudinal analysis of biomarker testing journeys of individual patients, which identifies opportunities for earlier testing and treatment; DXRX lab benchmarking that enables laboratories to gain competitive edge and compare key criteria to others in the industry providing metrics, such as disease, testing and methodology, market share, turnaround time, and laboratory leadership in these areas; DXRX test reimbursement, which enables pharma customers to engage with laboratories to fund the introduction of novel companion diagnostics, as well as reducing the lag time in test adoption; and DXRX test signal that delivers a real-time alert of a testing event, which allows pharma customers to identify therapeutically actionable patients in the previous weeks. In addition, it offers diagnostic landscape, planning, implementation, and tracking services; and consulting services for precision medicine diagnostics. Further, the company provides test standardization, test quality assessment, test report optimization, laboratory tech support, test access and reimbursement, laboratory training, and educational resources services. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 23,699 21.51% | 19,504 39.88% | |||||||
Cost of revenue | 26,777 | 19,173 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (3,078) | 331 | |||||||
NOPBT Margin | 1.70% | ||||||||
Operating Taxes | (692) | (246) | |||||||
Tax Rate | |||||||||
NOPAT | (2,386) | 577 | |||||||
Net income | (1,746) -341.16% | 724 29.06% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (49) | 31 | |||||||
BB yield | 0.07% | -0.05% | |||||||
Debt | |||||||||
Debt current | 146 | 124 | |||||||
Long-term debt | 2,264 | 2,410 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 88 | 79 | |||||||
Net debt | (14,257) | (34,443) | |||||||
Cash flow | |||||||||
Cash from operating activities | 1,311 | 5,148 | |||||||
CAPEX | (125) | (4,870) | |||||||
Cash from investing activities | (4,209) | (4,870) | |||||||
Cash from financing activities | (239) | (132) | |||||||
FCF | 5,234 | 1,216 | |||||||
Balance | |||||||||
Cash | 16,667 | 19,841 | |||||||
Long term investments | 17,136 | ||||||||
Excess cash | 15,482 | 36,002 | |||||||
Stockholders' equity | 4,212 | 5,651 | |||||||
Invested Capital | 37,867 | 37,848 | |||||||
ROIC | 1.52% | ||||||||
ROCE | 0.75% | ||||||||
EV | |||||||||
Common stock shares outstanding | 84,227 | 86,090 | |||||||
Price | 0.87 15.23% | 0.76 -25.98% | |||||||
Market cap | 73,277 12.74% | 64,998 -24.98% | |||||||
EV | 59,020 | 30,555 | |||||||
EBITDA | 1,695 | 3,339 | |||||||
EV/EBITDA | 34.82 | 9.15 | |||||||
Interest | 66 | 122 | |||||||
Interest/NOPBT | 36.86% |